Physician profile
Deanne Wirth
NPI 1982231684
$1,532.17
in general payments reported to CMS, 2019-2025
20 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.16 · 2023: $345 · 2024: $842 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $275.73 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $271.17 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $179.22 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $174.13 | 2023-2025 | |
| Amgen INC. | $161.11 | 2023-2025 | Repatha, Uplizna |
| Eisai INC. | $67.30 | 2024-2025 | |
| Abbvie INC. | $46.47 | 2024-2025 | |
| Dexcom, INC. | $44.11 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $39.56 | 2023-2024 | Trelegy Ellipta, Bexsero, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.56 | 2023-2025 | Jardiance |
| Exact Sciences Corporation | $34.80 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $32.07 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $26.32 | 2023-2024 | |
| Biogen, INC. | $26.18 | 2024 | Vumerity |
| Inspire Medical Systems, INC. | $25.40 | 2024 | Inspire |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23.31 | 2024 | Veozah |
| Edwards Lifesciences Corporation | $21.16 | 2022 | |
| Ucb, INC. | $16.50 | 2023 | |
| Abbott Laboratories | $16.14 | 2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $13.93 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanne Wirth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.